Join
Live feed
·
PRReleasevia Quantisnow
Aerie Pharmaceuticals Inc. logo

Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
AERI· Aerie Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AERI (Aerie Pharmaceuticals Inc.) and more on Quantisnow.